Oligomeric forms of amyloid-beta protein in plasma as a potential blood-based biomarker for Alzheimer's disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, Min Jeong | - |
dc.contributor.author | Yi, SangHak | - |
dc.contributor.author | Han, Jee-Young | - |
dc.contributor.author | Park, So Young | - |
dc.contributor.author | Jang, Jae-Won | - |
dc.contributor.author | Chun, In Kook | - |
dc.contributor.author | Kim, Sang Eun | - |
dc.contributor.author | Lee, Byoung Sub | - |
dc.contributor.author | Kim, Gwang Je | - |
dc.contributor.author | Yu, Ji Sun | - |
dc.contributor.author | Lim, Kuntaek | - |
dc.contributor.author | Kang, Sung Min | - |
dc.contributor.author | Park, Young Ho | - |
dc.contributor.author | Youn, Young Chul | - |
dc.contributor.author | An, Seong Soo A. | - |
dc.contributor.author | Kim, SangYun | - |
dc.date.available | 2020-02-27T16:41:16Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2017-12-15 | - |
dc.identifier.issn | 1758-9193 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5368 | - |
dc.description.abstract | Background: Soluble amyloid-beta (A beta) oligomers are the major toxic substances associated with the pathology of Alzheimer's disease (AD). The ability to measure A beta oligomer levels in the blood would provide simple and minimally invasive tools for AD diagnostics. In the present study, the recently developed Multimer Detection System (MDS) for AD, a new enzyme-linked immunosorbent assay for measuring A beta oligomers selectively, was used to detect A beta oligomers in the plasma of patients with AD and healthy control individuals. Methods: Twenty-four patients with AD and 37 cognitively normal control individuals underwent extensive clinical evaluations as follows: blood sampling; detailed neuropsychological tests; brain magnetic resonance imaging; cerebrospinal fluid (CSF) measurement of A beta 42, phosphorylated tau protein (pTau), and total tau protein (tTau); and C-11-Pittsburgh compound B (PIB) positron emission tomography. Pearson's correlation analyses between the estimations of A beta oligomer levels by MDS and other conventional AD biomarkers (CSF A beta 42, pTau, and tTau, as well as PIB standardized uptake value ratio [ PIB SUVR]) were conducted. ROC analyses were used to compare the diagnostic performance of each biomarker. Results: The plasma levels of A beta oligomers by MDS were higher in patients with AD than in normal control individuals, and they correlated well with conventional AD biomarkers (levels of A beta oligomers by MDS vs. CSF A Chi 42, r = -0.443; PIB SUVR, r = 0.430; CSF pTau, r = 0.530; CSF tTau, r = 0.604). The sensitivity and specificity of detecting plasma A beta oligomers by MDS for differentiating AD from the normal controls were 78.3% and 86.5%, respectively. The AUC for plasma A beta oligomers by MDS was 0.844, which was not significantly different from the AUC of other biomarkers (p = 0.250). Conclusions: Plasma levels of A beta oligomers could be assessed using MDS, which might be a simple, noninvasive, and accessible assay for evaluating brain amyloid deposition related to AD pathology. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.relation.isPartOf | ALZHEIMERS RESEARCH & THERAPY | - |
dc.subject | CEREBROSPINAL-FLUID | - |
dc.subject | TOTAL TAU | - |
dc.subject | BRAIN | - |
dc.subject | DIAGNOSIS | - |
dc.subject | BETA-AMYLOID((1-42)) | - |
dc.title | Oligomeric forms of amyloid-beta protein in plasma as a potential blood-based biomarker for Alzheimer's disease | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000418227800002 | - |
dc.identifier.doi | 10.1186/s13195-017-0324-0 | - |
dc.identifier.bibliographicCitation | ALZHEIMERS RESEARCH & THERAPY, v.9 | - |
dc.identifier.scopusid | 2-s2.0-85038116358 | - |
dc.citation.title | ALZHEIMERS RESEARCH & THERAPY | - |
dc.citation.volume | 9 | - |
dc.contributor.affiliatedAuthor | An, Seong Soo A. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Amyloid-beta protein | - |
dc.subject.keywordAuthor | Oligomer | - |
dc.subject.keywordAuthor | Alzheimer&apos | - |
dc.subject.keywordAuthor | s disease | - |
dc.subject.keywordAuthor | Biomarker | - |
dc.subject.keywordPlus | CEREBROSPINAL-FLUID | - |
dc.subject.keywordPlus | TOTAL TAU | - |
dc.subject.keywordPlus | BRAIN | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | BETA-AMYLOID((1-42)) | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.